OncoMatch/Clinical Trials/NCT01185132
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
Is NCT01185132 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for breast cancer.
In the setting of radiotherapy as part of breast-conservation therapy for patients with early stage breast cancer, the novel planning and delivery method of intensity modulated radiotherapy is an effective and safe alternative to the commonly-used standard 3D-conformal external beam radiotherapy, spares more normal breast and lung tissue, and may lead to improved clinical outcomes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage TIS (AJC)
Grade: high nuclear grade DCIS
Histologically confirmed disease (AJC Classification): Tis, T1, T2 (≤ 3.0 cm), N0, M0.
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rocky Mountain Cancer Centers - Aurora · Aurora, Colorado
- Rocky Mountain Cancer Centers - Boulder · Boulder, Colorado
- Rocky Mountain Cancer Centers - Lakewood · Lakewood, Colorado
- Rocky Mountain Cancer Centers - Littleton · Littleton, Colorado
- Rocky Mountain Cancer Centers - Thornton · Thornton, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT01185132 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage TIS is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages